ArticleCell reports2022
Oncogenic Vav1-Myo1f induces therapeutically targetable macrophage-rich tumor microenvironment in peripheral T cell lymphoma.
Open access · goldAbstract read
In one paragraph
Article in Cell reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 22 citations in OpenAlex.
- Single-cell transcriptomics and machine-learning reveal M1 macrophage-driven progression from minimal change disease to focal segmental glomerulosclerosis.Renal failure · 2026Article
- T cell lymphomas: cancers of aberrant immune synapse signalling.Nature reviews. Immunology · 2026Review
- Serum free fatty acid promotes tumor progression and predicts golidocitinib sensitivity in peripheral T-cell lymphoma.Blood advances · 2026Article
- Screening macrophage polarization genes in spinal cord injury as therapeutic targets.PloS one · 2026Article
- Identification and Validation of BATF3 as a Promising Biomarker Gene for Peripheral T-cell Lymphoma.Current medicinal chemistry · 2026Article
- Case Report: Cutaneous niche-restricted malignant phenotypes in PTCL-NOS revealed by single-cell sequencing.Frontiers in oncology · 2026Article
- CDK9 is a dependency in GATA-3 driven and MCL-1 independent T-cell Lymphomas.Blood cancer journal · 2025Article
- Discrete genetic subtypes and tumor microenvironment signatures correlate with peripheral T-cell lymphoma outcomes.Leukemia · 2025Article
- MYO1F regulates T-cell activation and glycolytic metabolism by promoting the acetylation of GAPDH.Cellular & molecular immunology · 2025Article
- Review
- Macrophage polarization-related gene signature for risk stratification and prognosis of survival in gliomas.Journal of cellular and molecular medicine · 2024Article
- Pathobiology of nodal peripheral T-cell lymphomas: current understanding and future directions.Haematologica · 2023Review
- TCR Pathway Mutations in Mature T Cell Lymphomas.Journal of immunology (Baltimore, Md. : 1950) · 2023Review
- Advances in single-cell RNA sequencing and its applications in cancer research.Journal of hematology & oncology · 2023Review
- Update on histone deacetylase inhibitors in peripheral T-cell lymphoma (PTCL).Clinical epigenetics · 2023Review
- SOHO State of the Art Updates and Next Questions | New Pathways and New Targets in PTCL: Staying on Target.Clinical lymphoma, myeloma & leukemia · 2023Review
- Precise diagnosis and targeted therapy of nodal T-follicular helper cell lymphoma (T-FHCL).Frontiers in oncology · 2023Review
- PTCL, NOS: An update on classification, risk-stratification, and treatment.Frontiers in oncology · 2023Review
- How molecular advances may improve the diagnosis and management of PTCL patients.Frontiers in oncology · 2023Review
- Targeting Lymphoma-associated Macrophage Expansion via CSF1R/JAK Inhibition is a Therapeutic Vulnerability in Peripheral T-cell Lymphomas.Cancer research communications · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 5 institutions in 3 countries.
Jose R CortesInstitute for Cancer Genetics, Columbia University, New York, NY 10032, USA.
Ioan FilipDepartment of Systems Biology, Columbia University, New York, NY 10032, USA.
Robert AlberoInstitute for Cancer Genetics, Columbia University, New York, NY 10032, USA.
Juan A Patiño-GalindoDepartment of Systems Biology, Columbia University, New York, NY 10032, USA.
S Aidan QuinnInstitute for Cancer Genetics, Columbia University, New York, NY 10032, USA.
Wen-Hsuan W LinDepartment of Pathology and Cell Biology, Columbia University, New York, NY 10032, USA.
Anouchka P LaurentInstitute for Cancer Genetics, Columbia University, New York, NY 10032, USA.
Bobby B ShihInstitute for Cancer Genetics, Columbia University, New York, NY 10032, USA.
Jessie A BrownInstitute for Cancer Genetics, Columbia University, New York, NY 10032, USA.
Anisha J CookeInstitute for Cancer Genetics, Columbia University, New York, NY 10032, USA.
Adam MackeyInstitute for Cancer Genetics, Columbia University, New York, NY 10032, USA.
Jonah EinsonDepartment of Biomedical Informatics, Columbia University, New York, NY 10032, USA.
Sakellarios ZairisDepartment of Systems Biology, Columbia University, New York, NY 10032, USA.
Alfredo Rivas-DelgadoDepartment of Hematology, Hospital Clínic de Barcelona, Barcelona 08036, Spain.
Maria Antonella LaginestraExperimental Oncology Laboratory, IRCCS Istituto Ortopedico Rizzoli, Bologna 40136, Italy.
Stefano PileriDivision of Hematopathology, European Institute of Oncology IRCCS, Milan 20141, Italy.
Elias CampoHematopathology Unit, Department of Pathology, Hospital Clínic-IDIBAPS, Barcelona 08036, Spain.
Govind BhagatDepartment of Pathology and Cell Biology, Columbia University, New York, NY 10032, USA.
Adolfo A FerrandoInstitute for Cancer Genetics, Columbia University, New York, NY 10032, USA; Department of Systems Biology, Columbia University, New York, NY 10032, USA; Department of Pathology and Cell Biology, Columbia University, New York, NY 10032, USA; Department of Pediatrics, Columbia University, New York, NY 10032, USA.
Raul RabadanDepartment of Systems Biology, Columbia University, New York, NY 10032, USA; Department of Biomedical Informatics, Columbia University, New York, NY 10032, USA.
Teresa PalomeroInstitute for Cancer Genetics, Columbia University, New York, NY 10032, USA; Department of Pathology and Cell Biology, Columbia University, New York, NY 10032, USA. Electronic address: tp2151@columbia.edu.
Cancer Genetics (United States) · USColumbia University · USHospital Clínic de Barcelona · ESEuropean Institute of Oncology · ITIstituto Ortopedico Rizzoli · IT
Funding
Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Anil K Rustgi · 1985 to 2026
$115.3MTranslating Stress Response Targeted Therapy for B-Cell LymphomasP50CA192937 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI DALLA-FAVERA, RICCARDO, ZELENETZ, ANDREW D. · 2016 to 2020
$10.9MMolecular pathways and targeted therapies in human leukemiaR35CA210065 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI FERRANDO, ADOLFO A. · 2017 to 2021
$4.7MSingle-cell characterization of tumor and microenvironment co-evolution in Peripheral T-cell LymphomasU01CA243073 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI PALOMERO, TERESA, RABADAN, RAUL · 2019 to 2023
$3.0MRole and Mechanisms of VAV1 alterations in Peripheral T-cell LymphomasR01CA256341 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI PALOMERO, TERESA · 2021 to 2025
$1.8MThe role of RHOA G17V mutation in peripheral t-cell lymphomasR01CA197945 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI PALOMERO, TERESA · 2015 to 2019
$1.8MCAPRI: Columbia Cancer Training Program for Resident-InvestigatorsR38CA231577 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CREW, KATHERINE D, SCHWARTZ, GARY K · 2018 to 2021
$1.4MMechanism of Transformation in T-Cell Lymphomas: Identification of Therapeutic TargetsF31CA261153 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SHIH, BOBBY BEN · 2021 to 2023
$137kNCI NIH HHS F31 CA261153NCI NIH HHS P30 CA013696NCI NIH HHS P50 CA192937NCI NIH HHS R01 CA197945NCI NIH HHS R01 CA256341NCI NIH HHS R35 CA210065NCI NIH HHS R38 CA231577NCI NIH HHS U01 CA243073
Abstract
Peripheral T cell lymphoma not otherwise specified (PTCL-NOS) comprises heterogeneous lymphoid malignancies characterized by pleomorphic lymphocytes and variable inflammatory cell-rich tumor microenvironment. Genetic drivers in PTCL-NOS include genomic alterations affecting the VAV1 oncogene; however, their specific role and mechanisms in PTCL-NOS remain incompletely understood. Here we show that expression of Vav1-Myo1f, a recurrent PTCL-associated VAV1 fusion, induces oncogenic transformation of CD4
Indexed as
Lymphoma, T-Cell, PeripheralAnimalsGene FusionMacrophagesMiceMyosin Type IOncogenesProto-Oncogene Proteins c-vavTumor MicroenvironmentMyo1f protein, mouseMyosin Type IProto-Oncogene Proteins c-vavVav1 protein, mouseCP: CancerGATA3peripheral T cell lymphomaT cell differentiationtumor-associated macrophagestumor microenvironmentVAV1VAV1-MYO1F
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.